GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (OTCPK:APTOF) » Definitions » Total Assets

APTOF (Aptose Biosciences) Total Assets : $10.13 Mil (As of Dec. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences Total Assets?

Aptose Biosciences's Total Assets for the quarter that ended in Dec. 2024 was $10.13 Mil.

During the past 12 months, Aptose Biosciences's average Total Assets Growth Rate was 12.90% per year. During the past 3 years, the average Total Assets Growth Rate was 9.20% per year. During the past 5 years, the average Total Assets Growth Rate was 6.80% per year. During the past 10 years, the average Total Assets Growth Rate was 27.80% per year.

During the past 13 years, Aptose Biosciences's highest 3-Year average Total Assets Growth Rate was 150.60%. The lowest was -42.20%. And the median was 0.70%.

Total Assets is connected with ROA %. Aptose Biosciences's annualized ROA % for the quarter that ended in Dec. 2024 was -60.22%. Total Assets is also linked to Revenue through Asset Turnover. Aptose Biosciences's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.


Aptose Biosciences Total Assets Historical Data

The historical data trend for Aptose Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Total Assets Chart

Aptose Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.26 82.53 51.03 12.99 10.13

Aptose Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.99 12.80 10.95 10.93 10.13

Aptose Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aptose Biosciences's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=-4.543+14.67
=10.13

Aptose Biosciences's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=-4.543+14.67
=10.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptose Biosciences  (OTCPK:APTOF) Total Assets Explanation

Total Assets is connected with ROA %.

Aptose Biosciences's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-6.34/( (10.929+10.127)/ 2 )
=-6.34/10.528
=-60.22 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aptose Biosciences's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (10.929+10.127)/ 2 )
=0/10.528
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aptose Biosciences Total Assets Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
William G. Rice director, officer: Chair, President & CEO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Fletcher Payne officer: SR VP & Chief Fin. Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru officer: Chief Commercial Officer C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger director CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer director
Rafael Bejar officer: Chief Medical Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr. 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow officer: Senior VP & CFO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango officer: Senior VP, Chief Bus. Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3